These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 36732607)
41. Lichenoid dermatitis caused by thienopyridine derivatives. Galeone M; Scarfì F; Bassi A; Massi D; Difonzo EM; Francalanci S G Ital Dermatol Venereol; 2016 Oct; 151(5):565-6. PubMed ID: 25952285 [No Abstract] [Full Text] [Related]
42. Terbinafine-induced lichenoid drug eruption. Zheng Y; Zhang J; Chen H; Lai W; Maibach HI Cutan Ocul Toxicol; 2017 Mar; 36(1):101-103. PubMed ID: 26938740 [TBL] [Abstract][Full Text] [Related]
43. Profound sweating episodes and latanoprost. Kumar H; Sony P; Gupta V Clin Exp Ophthalmol; 2005 Dec; 33(6):675. PubMed ID: 16402972 [No Abstract] [Full Text] [Related]
44. Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis. Ghiam N; Ojong O; Vasile G; Romanelli P; Kerdel F Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423430 [TBL] [Abstract][Full Text] [Related]
45. Latanoprost and periocular skin color changes. Wand M; Ritch R; Isbey EK; Zimmerman TJ Arch Ophthalmol; 2001 Apr; 119(4):614-5. PubMed ID: 11296032 [No Abstract] [Full Text] [Related]
46. Serious spinal sequelae following the use of eye drops. Park JC; Jones DH Eye (Lond); 2010 Jun; 24(6):1109. PubMed ID: 19876072 [No Abstract] [Full Text] [Related]
47. Systemic side effects of topical latanoprost. Rajan MS; Syam P; Liu C Eye (Lond); 2003 Apr; 17(3):442-4. PubMed ID: 12724721 [No Abstract] [Full Text] [Related]
52. Update in glaucoma: the new pharmacotherapies. Latanoprost. Buys YM Can J Ophthalmol; 1998 Aug; 33(5):255-7; discussion 257-8. PubMed ID: 9740953 [No Abstract] [Full Text] [Related]
53. Guanfacine-induced lichenoid drug eruption in a child with autism and attention deficit hyperactivity disorder. Romanelli M; Rhodes A Pediatr Dermatol; 2014; 31(5):614-5. PubMed ID: 23869619 [TBL] [Abstract][Full Text] [Related]
54. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Mochizuki H; Itakura H; Yokoyama T; Takamatsu M; Kiuchi Y Jpn J Ophthalmol; 2010 Jul; 54(4):286-90. PubMed ID: 20700794 [TBL] [Abstract][Full Text] [Related]
55. Anastrozole-Associated Lichenoid Eruption. Ivory J; Sochat M; Galatowitsch J; Ghani S Am J Ther; 2020; 27(6):e658-e660. PubMed ID: 33156584 [No Abstract] [Full Text] [Related]
56. The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study. Tsuru T; Kitazawa Y; Usui M; Ueno S; Azuma I; Masuda K Jpn J Ophthalmol; 2008; 52(5):368-373. PubMed ID: 18991037 [TBL] [Abstract][Full Text] [Related]
57. Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition? de Unamuno-Bustos B; Ballester-Sánchez R; Sabater Marco V; Vilata-Corell JJ Actas Dermosifiliogr; 2014 Nov; 105(9):876-8. PubMed ID: 24666578 [No Abstract] [Full Text] [Related]
58. [In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T)]. Nagai N; Murao T; Oe K; Ito Y; Okamoto N; Shimomura Y Yakugaku Zasshi; 2011; 131(6):985-91. PubMed ID: 21628988 [TBL] [Abstract][Full Text] [Related]
59. Choroidal detachment after the use of topical latanoprost. Marques Pereira ML; Katz LJ Am J Ophthalmol; 2001 Dec; 132(6):928-9. PubMed ID: 11730664 [TBL] [Abstract][Full Text] [Related]
60. Latanoprost and cystoid macular edema: is there a causal relation? Schumer RA; Camras CB; Mandahl AK Curr Opin Ophthalmol; 2000 Apr; 11(2):94-100. PubMed ID: 10848227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]